CClinicalTrials.gg
CompletedNCT03407677ROTOoneUpdated Mar 3, 2021

The Impact of ROTO Track® in Helping Patients With Diabetes Rotate Their Insulin Injections Better

An interventional study of ROTO track® in Diabetes, sponsored by Peter Lommer. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-03.

Sponsored by Peter Lommer · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The ROTO track® is an electronic injection form and injection log for keeping track of injection sites in the abdominal region. The device attaches directly to the insulin pen and activates whenever the insulin pen is picked up. Small LED lights on the device will indicate where the next injection site is according to the individual patient's injection plan. By moving the pen and device to an "anchor point" in front of the navel, the device is able to start tracking where the insulin pen is being moved to. The device additionally contains a haptic interface to indicate to the user when the device has been moved to the next area in the injection plan.

The device registers the location, the time and the dosage automatically when the patient injects insulin with the pen

The rationale of the trial is that the ROTO track® can help patients rotate their injections sites and that this will provide the healthcare system with a new cost-effective tool for improving insulin injection techniques.

Read the detailed description

Both observational and interventional studies have reported that proper rotation of injection sites can be obtained through intensive injection technique training, education and follow up of patients. Furthermore, this has significant beneficial effects on daily glycaemic variations, hypoglycaemic events, long term blood glucose levels, and insulin dose requirements. This is however frequently not done appropriately in every day practice.

At a small workshop at Nordsjællands Hospital in November 2017 with patients with type 1 diabetes the value of a device to registrar time, dose and rotation of insulin injections were discussed. All patients considered their own injection patterns as satisfying - although only one in four used a systematic approach. Most patients relied on their healthcare provider to identify side effects like lipohypertrophy, half of the patients re-used needles more than once and two took injections through the clothes now and then. All subjects would prefer a simple and small device to be used with the pen for the lifetime of the pen to minimize time used for injections and attraction of attention from other people.

The hypothesis is that the ROTO track® can reduce the number of insulin injections in the same subcutaneous skin area as compared with standard insulin injection instructions in patients with type 1 diabetes. The reduction of injection in same skin area will be quantified by a rotation score

02

Conditions studied

  • Diabetes

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Written informed consent obtained before any trial related procedures are performed
  2. Male or female aged 18 years
  3. Type 1 diabetes with a duration of two or more years
  4. Treated with three or more daily pen injections of Novo Rapid™ in the abdominal region
  5. The subject must be willing and able to comply with trial protocol

Exclusion criteria

Exclusion Criteria:

  1. Blind or severely impaired eyesight
  2. History of alcohol or drug abuse
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Other
    ROTO Track

    The individual patient will serve as his/her own control before intervention with ROTO Track

    Device: ROTO track®

Interventions

  • DeviceROTO track®

    An electronic injection form and injection log for keeping track of injection sites in the abdominal region. The device attaches directly to the insulin pen and activates whenever the insulin pen is picked up.

05

What researchers measure

Primary outcomes

  1. rotation of insulin injections

    Number of insulin injections taken in a given subcutaneous skin area will be captured in a rotation score by the ROTO track® . The rotation score is a single ratio value that combines the distribution over the skin areas used with the time between re-use of a field. The value is set from 0 (meaning every injections in a single area) to 1 (meaning perfect rotation with the maximum possible time between two injections in the same skin area).

    Time frame: 6 days

Secondary outcomes

  1. rotation of insulin injections

    Number of insulin injections taken in a given subcutaneous skin area captured in a rotation score by the ROTO Track

    Time frame: 12 weeks

  2. number of insulin infiltrates

    documented by drawings and photos hereof

    Time frame: 12 weeks

  3. glucose variability

    measured by continuous glucose monitors

    Time frame: 12 weeks

  4. glycaemic control

    HbA1c

    Time frame: 12 weeks

  5. Insulin dose requirement

    captured i diaries

    Time frame: 12 weeks

  6. Hypoglycaemic events

    captured in diaries and by continuous glucose monitoring

    Time frame: 12 weeks

  7. Patient reported outcomes

    quality of life

    Time frame: 12 weeks

  8. Patient reported outcomes

    usability of the ROTO track®

    Time frame: 12 weeks

  9. Accuracy of the ROTO track® injection log

    assessed by comparison of diaries and data from the ROTO Track

    Time frame: 12 weeks

Other outcomes

  1. Additional effect of an app in combination with the ROTO Track

    Number of insulin injections taken in a given subcutaneous skin area - captured in the rotation score

    Time frame: Additional 12 weeks

  2. Insulin infiltrates - numbers

    drawings documented by photography

    Time frame: additional 12 weeks

  3. Insulin dose requirement

    from diaries

    Time frame: additional 12 weeks

  4. glycaemic control

    measured by HbA1c

    Time frame: additional 12 weeks

06

Study locations

1 site
  • Department of Clinical Research, Nordsjællands Hospital
    Hillerød, 3400, Denmark
07

Registry details

Key details

Study ID
NCT03407677
Lead sponsor
Peter Lommer
Responsible party
Peter Lommer (Head of Department, Endocrinology and Nephrology Department, Nordsjaellands Hospital) — Sponsor-investigator
First posted
Jan 23, 2018
Start date
Aug 27, 2018
Primary completion
Nov 20, 2019
Completion
Nov 27, 2019
Last update
Mar 3, 2021

Study contacts

Peter L Kristensen, MD, PhD
principal investigator · Department of Clinical Research, Nordsjællands Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion